Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
Radiation recall dermatitis (RRD) is an inflammatory reaction occurring in a previously irradiated area, precipitated by the administration of certain drugs. The drugs most commonly associated with RRD are intravenous antineoplastic agents. The frequency of development of this toxicity in clinical practice is unclear. We report a case of RRD induced by ixabepilone, an epothilone antineoplastic agent, with successful rechallenge utilizing an alternative dosing regimen.
School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA.
J Neal
JN
Ford
Michael
M
Newton
Christen
C
Jordan
Jame
J
Abraham
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy / Q000009:adverse effects; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D019008:Drug Resistance, Neoplasm; D034261:Epothilones / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011855:Radiodermatitis / Q000139:chemically induced / Q000517:prevention & control*; D000068878:Trastuzumab; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D034261:Epothilones; D050257:Tubulin Modulators; C430592:ixabepilone; D000068878:Trastuzumab